Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Pareto8020on Aug 12, 2021 7:03pm
277 Views
Post# 33698543

What is the CURE for SBM?

What is the CURE for SBM?I wonder how much CURE is getting paid - likely too much whatever it is.  All they've done is up SBM's tweet #'s.  Not CURE's fault though but SBM and Howard's for not having anything to promote.  They bring them on at the end of last year expecting all these milestones to be reached and then like every scenario before - SBM can't close a deal or finalize anything!  Now with 4 months left to go in their contract Howard still doesn't have anything for them to promote! So another blunder wasting valuable dollars by learn-as-you-go part time CEO Howard.

I've been invested too many years now and if they can't close something meaningful by Thanksgiving it's time to start shedding shares like a bad habit.  

Sirona Biochem Signs Agreement with Luxembourg-based CURE Intelligence for Social Media and Communications Support


VANCOUVER, BC Dec. 15, 2020 /CNW/ - Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) (" Sirona ") is pleased to announce that it has signed an agreement with Luxembourg -based analytics and marketing specialist CURE Intelligence to manage online analytics and social media communication.

The agreement was signed December 8 th and will continue for a period of 12 months.

"We realize the power of social media in bringing awareness of our technology to a greater audience both efficiently and with improved content. We have been working to increase our virtual presence and have now found a partner that can reach more potential partners and expand our business development," said Dr. Howard Verrico , CEO of Sirona Biochem. "We look forward to this new relationship with the team at CURE. During our due diligence, we've been impressed with their commitment to hard work and their ability to add significant value to our communications."

"Sirona Biochem is on the verge of a new chapter in the company's history. After years of research and development of its platform technology, the company is about to commercialize one of its compounds and achieve other significant milestones. We look forward to raising awareness of Sirona and its breakthrough technology among targeted audiences through regular effective content and data-driven distribution on social media," comments Marco Feiten , Managing Director at CURE Intelligence.

<< Previous
Bullboard Posts
Next >>